Wanbury’s ₹100 Crore Bet on Next-Gen API Manufacturing

Wanbury, a leading pharmaceutical company, has announced the commencement of its state-of-the-art active pharmaceutical ingredient (API) manufacturing facility at Tanuku, Andhra Pradesh, marking a key milestone in the company’s growth strategy.

The company is targeting revenue of approximately ₹100 crore from new products, including high-value APIs such as anti-tussive, antidepressant, and anticoagulant molecules. This strategic expansion is aimed at meeting rising global demand, strengthening Wanbury’s position in the API segment, and enhancing its presence across domestic and international markets.

Wanbury plans to begin commercial production by Q4 FY26, with revenue growth expected to be driven by the scale-up of these critical API offerings. The facility is designed to support the manufacture of complex and high-quality products aligned with global regulatory standards.

With an investment of over ₹100 crore, the Tanuku plant underscores Wanbury’s commitment to quality, innovation, and global expansion. The new facility is expected to play a pivotal role in increasing the company’s market share while ensuring a reliable supply of high-quality pharmaceutical ingredients to healthcare markets worldwide.

News by Rahul Yelligetti.